4587 Stock Overview
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
PeptiDream Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,406.00 |
52 Week High | JP¥2,549.00 |
52 Week Low | JP¥1,039.00 |
Beta | 0.77 |
1 Month Change | -7.59% |
3 Month Change | -2.83% |
1 Year Change | -23.25% |
3 Year Change | -72.21% |
5 Year Change | -73.57% |
Change since IPO | 95.62% |
Recent News & Updates
Shareholder Returns
4587 | JP Biotechs | JP Market | |
---|---|---|---|
7D | 2.7% | -2.0% | 1.0% |
1Y | -23.3% | -23.2% | 38.6% |
Return vs Industry: 4587 matched the JP Biotechs industry which returned -23.2% over the past year.
Return vs Market: 4587 underperformed the JP Market which returned 38.6% over the past year.
Price Volatility
4587 volatility | |
---|---|
4587 Average Weekly Movement | 7.6% |
Biotechs Industry Average Movement | 7.8% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.3% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4587 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4587's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 725 | Patrick Crawford Reid | https://www.peptidream.com |
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage.
PeptiDream Inc. Fundamentals Summary
4587 fundamental statistics | |
---|---|
Market cap | JP¥182.23b |
Earnings (TTM) | JP¥3.04b |
Revenue (TTM) | JP¥28.71b |
60.0x
P/E Ratio6.3x
P/S RatioIs 4587 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4587 income statement (TTM) | |
---|---|
Revenue | JP¥28.71b |
Cost of Revenue | JP¥11.49b |
Gross Profit | JP¥17.22b |
Other Expenses | JP¥14.18b |
Earnings | JP¥3.04b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | 23.42 |
Gross Margin | 59.97% |
Net Profit Margin | 10.57% |
Debt/Equity Ratio | 55.1% |
How did 4587 perform over the long term?
See historical performance and comparison